This is a randomized, multi-centre, open-label, parallel arm, active controlled, comparative clinical study, to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Hetero-Semaglutide injection and RMP-Semaglutide injection (Ozempic, Novo Nordisk) in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin. Patients who are on Metformin greater than or equal to 1500mg/day for about 12 weeks before screening and glycosylated haemoglobin (HbA1c) greater than or equal to 7.0 percentage and less than or equal to 11.0 percentage at screening will be enrolled in this study. The study will consist of up to 14-days screening period, 24 weeks treatment period. Approximately 312 patients will be randomized into either Test arm or Comparator arm. Patients will receive either Hetero Semaglutide Injection or Reference Injection of 0.25 mg, 0.5 mg, 1mg and 2 mg dose will be administer Subcutaneously in the abdomen, thigh, or upper arm once weekly, on the same day each week, at any time of day, with or without meals with initial Starting dose of 0.25 mg once weekly for 4 weeks and followed by Dose Titration. All patients will be provided with diary at the time of enrolment along with glucometer to record details about study drug administration, adverse events (AEs), hypoglycaemic episodes, rescue medications (if any) and self-monitoring of blood glucose levels. Patients will be required to bring completed diary and glucometer at each visit. Patient will be provided with ‘instruction for use’ document and will be trained on how to administer the study product. Patients will continue to receive metformin as per pre study dose for entire study duration of 24 weeks.